Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Position Raised by Barclays PLC

Barclays PLC increased its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 356.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 247,280 shares of the company's stock after purchasing an additional 193,046 shares during the quarter. Barclays PLC owned 0.12% of Taysha Gene Therapies worth $513,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in TSHA. Creative Planning acquired a new position in shares of Taysha Gene Therapies during the 3rd quarter worth about $28,000. China Universal Asset Management Co. Ltd. raised its stake in Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company's stock valued at $79,000 after acquiring an additional 17,446 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Taysha Gene Therapies during the 3rd quarter valued at approximately $85,000. Scientech Research LLC purchased a new stake in Taysha Gene Therapies during the 2nd quarter valued at approximately $97,000. Finally, SG Americas Securities LLC purchased a new position in shares of Taysha Gene Therapies during the 3rd quarter worth approximately $129,000. 77.70% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

TSHA has been the subject of several research analyst reports. Chardan Capital reaffirmed a "buy" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Canaccord Genuity Group increased their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a "buy" rating in a report on Friday, November 15th. JMP Securities restated a "market outperform" rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research report on Monday, January 6th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $6.63.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA traded down $0.05 during midday trading on Friday, hitting $1.53. 1,924,619 shares of the company's stock were exchanged, compared to its average volume of 2,141,908. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The stock's 50 day moving average price is $2.14 and its 200-day moving average price is $2.11. The firm has a market cap of $313.56 million, a P/E ratio of 2.43 and a beta of 0.95. Taysha Gene Therapies, Inc. has a twelve month low of $1.19 and a twelve month high of $4.32.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.